Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMKM6BY)

Drug Name
Cyclopenta[d]pyrimidine derivative 1 Drug Info
Synonyms PMID28270010-Compound-Figure28
Cross-matching ID
PubChem CID
76283234
TTD Drug ID
DMKM6BY

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting NT-3 growth factor receptor (TrkC)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Entrectinib DMMPTLH Non-small-cell lung cancer 2C25 Approved [2]
Larotrectinib DM26CQR Solid tumour/cancer 2A00-2F9Z Approved [3]
MK-2461 DM21WBH Alzheimer disease 8A20 Phase 1/2 [4]
Altiratinib DMUJCBT Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
PMID28270021-Compound-WO2016054807Example1 DMD5QEL Chronic pain MG30 Patented [5]
PMID28270010-Compound-Figure24-b DM0QHLK N. A. N. A. Patented [1]
Pyrrolo[2,3-d]pyrimidine derivative 4 DME0WSR Chronic pain MG30 Patented [5]
3-amino-5-benzyl-substituted indazole derivative 1 DMFDURZ Chronic pain MG30 Patented [5]
PMID28270010-Compound-Figure5-1 DM2YAPJ N. A. N. A. Patented [1]
PMID28270021-Compound-WO2015042088Example4 DM6KXOQ Chronic pain MG30 Patented [5]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting BDNF/NT-3 growth factors receptor (TrkB)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Entrectinib DMMPTLH Non-small-cell lung cancer 2C25 Approved [2]
Larotrectinib DM26CQR Solid tumour/cancer 2A00-2F9Z Approved [3]
MK-2461 DM21WBH Alzheimer disease 8A20 Phase 1/2 [4]
PMID28270021-Compound-WO2016054807Example1 DMD5QEL Chronic pain MG30 Patented [5]
PMID28270010-Compound-Figure24-b DM0QHLK N. A. N. A. Patented [1]
Pyrrolo[2,3-d]pyrimidine derivative 4 DME0WSR Chronic pain MG30 Patented [5]
3-amino-5-benzyl-substituted indazole derivative 1 DMFDURZ Chronic pain MG30 Patented [5]
PMID28270010-Compound-Figure5-1 DM2YAPJ N. A. N. A. Patented [1]
PMID28270021-Compound-WO2015042088Example4 DM6KXOQ Chronic pain MG30 Patented [5]
PMID28270010-Compound-Figure5-2 DMK3GRZ N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
BDNF/NT-3 growth factors receptor (TrkB) TTKN7QR NTRK2_HUMAN Inhibitor [1]
NT-3 growth factor receptor (TrkC) TTXABCW NTRK3_HUMAN Inhibitor [1]

References

1 Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
3 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
4 MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
5 Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.